Patients and those who care for them want access to new drugs, devices and biological products as quickly as possible, while also being assured that the benefits of these products outweigh the risks. The Clinical Trials Transformation Initiative (CTTI) is a public-private partnership of over 80 members that strive to identify and drive adoption of practices that will increase the quality and efficiency of clinical trials.
CTTI was established in 2007 through a partnership between the FDA and Duke, and is administered through the Duke Translational Medicine Institute.
CTTI’s approach includes conducting projects to better understand the range of current practices, assess alternative approaches, understand barriers to change, and propose recommendations for improvement. Funding from member organizations provides support for projects and infrastructure, according to a published fee schedule. The Executive Committee oversees the use of these funds.
Resources provided by the CTTI include: